Sensei Bio sets CEO salary at $425K, SVP at $400K; retention bonuses tied to Feb 2026

Sensei Biotherapeutics, Inc.

Annual base salaries: Christopher Gerry $425,000, Josiah Craver $400,000, effective Nov 14, 2025.
Each eligible for target annual bonus equal to 40% of base salary beginning FY 2026.
First retention bonus equals full 2025 target bonus if employed through Feb 13, 2026 or terminated without cause.
Second retention bonus is prorated 2026 target bonus if terminated without cause before 2026 bonus payment; 2x multiplier if not change-in-control.
Severance benefits require execution of separation agreement and release of claims.

item 5.02

Machine-readable event card

schema_version: secwatch.filing_event.v1
accession: 0001193125-25-331113
form_type: 8-K
ticker: SNSE
cik: 0001829802
company_name: Sensei Biotherapeutics, Inc.
filed_at: 2025-12-23T23:59:59+00:00
discovered_at: 2026-05-14T18:02:40.674504+00:00
generated_at: 2026-05-16T12:17:15.299408+00:00
sec_items: ["5.02"]
event_type: leadership
sentiment: neutral
materiality_score: 0.4
confidence: high
secwatch_canonical_url: https://secwatch.observer/filing/0001193125-25-331113
json_url: https://secwatch.observer/filing/0001193125-25-331113.json
markdown_url: https://secwatch.observer/filing/0001193125-25-331113.md
text_url: https://secwatch.observer/filing/0001193125-25-331113.txt
edgar_index_url: https://www.sec.gov/Archives/edgar/data/1829802/000119312525331113/0001193125-25-331113-index.htm
edgar_primary_document_url: https://www.sec.gov/Archives/edgar/data/1829802/000119312525331113/d68669d8k.htm
generated_by_model: deepseek-v4-flash:cloud@v2
review_status: machine_generated
human_reviewed: false
corrected: false
correction_note: null
correction_timestamp: null
superseded_by: null

JSON Markdown Plain text

Source: SEC EDGAR

accession 0001193125-25-331113

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.